Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Proto Labs, Inc. (Protolabs) (NYSE: PRLB) provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Minnesota corporation with common stock listed on the New York Stock Exchange, Protolabs submits periodic and current reports that document its financial condition, operating results, and significant corporate events.
Investors researching PRLB can use this page to review annual reports on Form 10-K and quarterly reports on Form 10-Q, which present audited and interim financial statements, revenue by service line (Injection Molding, CNC Machining, 3D Printing, Sheet Metal, and Other Revenue), and discussions of non-GAAP measures such as adjusted EBITDA, non-GAAP gross margin, and non-GAAP net income. These filings explain how management evaluates performance and how digital factory and Protolabs Network fulfillment contribute to overall results.
The page also aggregates current reports on Form 8-K, which Protolabs uses to announce material events. Recent 8-K filings reference quarterly earnings press releases and leadership changes, including the appointment of a Chief Technology and AI Officer and related executive transitions. Such filings may also incorporate press releases as exhibits, giving readers direct access to management commentary and outlook statements.
Alongside these core reports, users can monitor exhibits related to executive compensation, inducement equity awards under NYSE Rule 303A.08, and severance arrangements referenced in executive agreements. Insider transaction reports on Form 4, proxy statements on Schedule 14A, and other ownership or governance-related filings, when available, help investors understand how executives and directors are compensated and how they hold or transact in PRLB shares.
Stock Titan enhances this information with AI-powered summaries that highlight key points in lengthy documents, such as revenue trends, margin drivers, and notable risk factors. Real-time updates from EDGAR ensure that new Protolabs filings, including 10-K, 10-Q, 8-K, and Form 4 reports, are quickly reflected, allowing users to review the underlying disclosures while relying on AI-generated explanations to interpret complex accounting and regulatory language.
Proto Labs, Inc. (PRLB)3,718 shares of common stock as a restricted stock unit grant at a price of $0, increasing direct beneficial ownership to 3,718 shares. The filing also reports a grant of an employee stock option for 6,818 shares of common stock with a $47.07 exercise price, expiring on 11/17/2035.
The restricted stock units vest annually over four years starting on November 15, 2026, and the stock option vests on the same schedule. This structure is designed so that the officer earns the awards gradually over time, which can help align long-term incentives with company performance and retention.
Disciplined Growth Investors, Inc. filed Amendment No. 6 to a Schedule 13G reporting beneficial ownership of 2,592,373 Proto Labs (PRLB) common shares, representing 10.9% of the class as of 09/30/2025.
The filer reports sole voting power over 2,316,889 shares and sole dispositive power over 2,592,373 shares, with no shared voting or dispositive power. The reporting person is classified as an investment adviser (IA).
In its certification, the filer states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Proto Labs.
PRLB filed a Form 144 for a proposed sale of 9,710 common shares, with an aggregate market value of $471,629.27. The shares may be sold through Morgan Stanley Smith Barney LLC, with an approximate sale date of 11/07/2025 on the NYSE. The securities were acquired primarily via restricted stock vesting under a registered plan and an employee stock purchase plan, including tranches such as 1,567 shares vested on 02/13/2024 and 797 shares purchased on 11/15/2023.
Proto Labs (PRLB) reported Q3 2025 results. Revenue rose to
Growth was led by the U.S. segment, where revenue increased
Year-to-date revenue reached
Proto Labs, Inc. (PRLB) furnished an 8-K announcing its third quarter 2025 financial results. The company reported the news via a press release that is attached to the filing as Exhibit 99.1 and incorporated by reference.
The filing is administrative in nature and points readers to the press release for the full results.
Proto Labs (PRLB)Chief Technology & AI Officer and indicated no securities are beneficially owned.
The filing was made by one reporting person and includes a Power of Attorney as an exhibit.
Proto Labs, Inc. reported a leadership change in its technology organization. On October 3, 2025, the company announced that Chief Technology Officer Oleg Ryaboy will depart and cease to be an employee effective November 2, 2025, and is no longer an executive officer as of that notice date.
Marc Kermisch has been appointed as the new Chief Technology & AI Officer, effective October 13, 2025, marking a transition that adds explicit responsibility for artificial intelligence. Upon departure, Mr. Ryaboy will receive severance benefits under the company’s existing Form of Executive Severance Agreement. The company also issued a press release detailing this leadership transition.
Disciplined Growth Investors, Inc. reports beneficial ownership of 2,722,011 shares of Proto Labs Inc. common stock, representing 11.4% of the outstanding class. The filer states it has sole voting power over 2,446,527 shares and sole dispositive power over all 2,722,011 shares, and that the securities were acquired and are held in the ordinary course of business rather than to influence control. The filing lists the issuers principal office in Maple Plain, Minnesota, and the reporting persons office in Minneapolis. The statement is signed by the firm's Chief Compliance Officer on 08/14/2025.
Proto Labs (PRLB) Form 4: President & CEO Suresh Krishna bought 1,725 common shares on 08/04/2025 in open-market transactions coded “P.” The weighted-average purchase price was $43.51 (range $43.47-$43.53), implying an aggregate outlay of roughly $75.5 thousand. Following the purchase, Krishna’s direct beneficial ownership rose to 18,021 shares, up about 11% from the prior holding. No sales, derivative transactions, or other insiders were reported in this filing.
The form contains no amendments, 10b5-1 notation, or additional footnotes beyond the pricing breakdown, and it does not reference any derivative securities. The filing therefore reflects a single, straightforward insider purchase that increases executive equity exposure.